10-Day Rally Sends Johnson & Johnson Stock Up 9.3%
Johnson & Johnson (JNJ) stock hit day 10 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 9.3% return. The company has gained about $42 Bil in value over the last 10 days, with its current market capitalization at about $491 Bil. The stock remains 44.4% above its value at the end of 2024. This compares with year-to-date returns of 12.3% for the S&P 500.
Johnson & Johnson’s recent streak reflects robust pharmaceutical innovation, highlighted by key FDA drug approvals for Caplyta and Darzalex Faspro. The strategic $3.05 billion Halda Therapeutics acquisition bolsters its oncology pipeline, fueling investor confidence alongside optimistic analyst upgrades and raised price targets.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There are only a couple of things to fear in JNJ stock given its overall Strong operating performance and financial condition. This is aligned with the stock’s High valuation because of which we think it is Fairly Priced (see Buy or Sell JNJ).
For quick background, JNJ provides healthcare products globally, including baby care, pharmaceuticals for inflammatory diseases, and MedTech electrophysiology solutions for cardiovascular treatment.
Comparing JNJ Stock Returns With The S&P 500
The following table summarizes the return for JNJ stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | JNJ | S&P 500 |
|---|---|---|
| 1D | 0.4% | 1.0% |
| 10D (Current Streak) | 9.3% | -1.9% |
| 1M (21D) | 5.9% | -2.0% |
| 3M (63D) | 15.1% | 2.5% |
| YTD 2025 | 44.4% | 12.3% |
| 2024 | -4.8% | 23.3% |
| 2023 | -8.6% | 24.2% |
| 2022 | 6.0% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 46 S&P constituents with 3 days or more of consecutive gains and 20 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 23 | 10 |
| 4D | 19 | 3 |
| 5D | 1 | 5 |
| 6D | 0 | 0 |
| 7D or more | 3 | 2 |
| Total >=3 D | 46 | 20 |
Key Financials for Johnson & Johnson (JNJ)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $85.2 Bil | $88.8 Bil |
| Operating Income | $23.4 Bil | $22.1 Bil |
| Net Income | $35.2 Bil | $14.1 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $23.7 Bil | $24.0 Bil |
| Operating Income | $6.8 Bil | $7.2 Bil |
| Net Income | $5.5 Bil | $5.2 Bil |
While JNJ stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.